Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: Results of intergroup 0159/cancer and leukemia group B 9480

Cancer

Volumn 101, Issue 10, 2004, Pages 2202-2208

  Ahles, Tim A ^a   Herndon II, James E ^b   Small, Eric J ^c   Vogelzang, Nicholas J ^d   Kornblith, Alice B ^e   Ratain, Mark J ^d   Stadler, Walter ^d   Palchak, David ^f   Marshall, M Ernest ^g   Wilding, George ^h   Petrylak, Daniel ⁱ   Holland, Jimmie C ^j  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b Cancer and Leukemia Group B Statistical Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g Southeast Cancer Control Consortium   (United States)

^h UNIVERSITY OF WISCONSIN   (United States)

ⁱ New York Presbyterian Hospital Columbia University Medical Center   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

Hormone refractory adenocarcinoma; Prostate carcinoma; Quality of life; Suramin

Indexed keywords

FLUDROCORTISONE; HYDROCORTISONE; OPIATE; SURAMIN;

ADULT; AGED; ARTICLE; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG MEGADOSE; FUNCTIONAL ASSESSMENT; HISTOPATHOLOGY; HUMAN; LEUKEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PAIN ASSESSMENT; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CARCINOMA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SURAMIN;

EID: 7644240078     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20655     Document Type: Article

References (15)

1. Bal DG. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:11-36.
2. Small EJ, Halabi S, Ratain MJ, et al. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of Intergroup 0159, Cancer and Leukemia Group B 9480. J Clin Oncol. 2002;20:3369-3375.
3. Curran D, Fossa S, Aaronson N, et al. Baseline quality of life of patients with advanced prostate cancer. European Organization for Research and Treatment of Cancer (EORTC), Genito-Urinary Tract Cancer Cooperative Group (GUT-CCG). Eur J Cancer. 1997;33:1809-1814.
4. Litwin MS, Lubeck DP, Stoddard ML, Pasta DJ, Flanders SC, Henning JM. Quality of life before death for men with prostate cancer: results from the CaPSURE database. J Urol. 2001;165:871-875.
5. Penson DF, Litwin MS, Aaronson NK. Health related quality of life in men with prostate cancer. J Urol. 2003;169:1653-1661.
6. Small EJ, Meyer M, Marshall ME, et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized Phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol. 2000;18:1440-1450.
7. Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol. 1999;17:1654-1663.
8. Kornblith AB, Holland JC. A model for quality-of-life research from the Cancer and Leukemia Group B: the telephone interview, conceptual approach to measurement, and theoretical framework. J Natl Cancer Inst Monogr. 1996;20:55-62.
9. Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-Prostate instrument. Urology. 1997;50:920-928.
10. Cella D, Hahn EA, Dineen K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res. 2002;11:207-221.
11. Radloff LS. The CES-D: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385-392.
12. Plutchick R, Conte HR. Self-report scales for the measurement of depression. Psychiatr Ann. 1989;19:367-371.
13. Daut RL, Cleeland CS, Flannery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 1983;14:197-210.
14. Cleeland CS. Pain control: public and physician's attitudes. In: Hill CS, Fields WS, editors. Advances in pain research and therapy. Volume 11. Drug treatment of cancer pain in a drug oriented society. New York: Raven Press, 1989:81-89.
15. Masters Steedman S, Middaugh SJ, Kee WG, Carson DS, Harden RN, Miller MC. Chronic-pain medications: equivalence levels and method of quantifying usage. Clin J Pain. 1992;8:204-214.